Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 12/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | STAT1 | P42224 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL486020 | 0.91 | F2R (0.61) | F2RNPC1RAB9AMAPTSTAT1 | |
| SCHEMBL1055207 | 0.89 | F2R (0.56) | F2RNPC1RAB9AMAPTSTAT1 | |
| SCHEMBL640806 | 0.86 | F2R (0.52) | F2RNPC1RAB9AMAPTSTAT1 | |
| SCHEMBL640569 | 0.86 | F2R (0.66) | F2RNPC1RAB9AMAPTSTAT1 | |
| SCHEMBL642622 | 0.86 | F2R (0.50) | F2RNPC1RAB9AMAPTSTAT1 | |
| SCHEMBL1056589 | 0.86 | F2R (0.41) | F2R | |
| SCHEMBL1055569 | 0.84 | HRH3 (0.44) | F2RS1PR1 | |
| SCHEMBL486191 | 0.84 | F2R (0.58) | F2RNPC1RAB9AMAPTSTAT1 | |
| SCHEMBL3724723 | 0.84 | F2R (0.60) | F2RNPC1RAB9AMAPTSTAT1 | |
| SCHEMBL1057305 | 0.82 | F2R (0.43) | F2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252948-A1 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| US-20130252948-A1 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| US-8440657-B2 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-14 | — | — | US | disclosed |
| US-8440657-B2 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-14 | — | — | US | disclosed |
| US-8440657-B2 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20120220563-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-30 | — | — | US | disclosed |
| US-20120220563-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-30 | — | — | US | disclosed |
| US-20120220563-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-30 | — | — | US | disclosed |
| US-8202862-B2 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8202862-B2 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8084469-B2 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20110021489-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021489-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021489-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| WO-2010136138-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136144-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136144-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305111-A1 | SUBSTITUTED PIPERIDINES | Bayer Schering Pharma (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305111-A1 | SUBSTITUTED PIPERIDINES | Bayer Schering Pharma (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305111-A1 | SUBSTITUTED PIPERIDINES | Bayer Schering Pharma (DE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021489-A1 | SUBSTITUTED PIPERIDINES | VHL, PIR, PIGO | F2R 1339/4885NPC1 308/4885RAB9A 2685/4885 |
| US-20100305111-A1 | SUBSTITUTED PIPERIDINES | VHL, PIR, PTGIS | F2R 1245/4885NPC1 343/4885RAB9A 2678/4885 |
| US-20120220563-A1 | Substituted piperidines | VHL, PIR, PIGO | F2R 1339/4885NPC1 308/4885RAB9A 2685/4885 |
| US-20130252948-A1 | Substituted piperidines | VHL, PIR, PTGIS | F2R 1245/4885NPC1 343/4885RAB9A 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.